Physician profile
Aisha Sethi
NPI 1568477222
$2,245.32
in general payments reported to CMS, 2019-2025
20 companies · $800 in 2025
The $800 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $340 · 2022: $216 · 2023: $280 · 2024: $609 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.58 |
| Education | $149.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $375.19 | 2021-2025 | Tremfya |
| Genzyme Corporation | $312.77 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $295.80 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $213.67 | 2021-2024 | Winlevi |
| Abbvie INC. | $201.23 | 2022-2025 | Rinvoq |
| Lilly USA, LLC | $168.92 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $131.83 | 2025 | Adbry |
| Dermavant Sciences, INC. | $81.50 | 2023 | Vtama |
| Novartis Pharmaceuticals Corporation | $75.46 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $64.71 | 2021 | |
| Galderma Laboratories, L.P. | $53.60 | 2021-2025 | Nemluvio |
| Incyte Corporation | $46.40 | 2022-2023 | Opzelura |
| Pfizer INC. | $44.94 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $44.18 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.07 | 2021-2024 | Cabtreo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $29.18 | 2024 | Hyrimoz |
| E.R. Squibb & Sons, L.L.C. | $21.05 | 2023 | Sotyktu |
| Dermira, INC. | $19.78 | 2021 | |
| Boston Scientific Corporation | $15.21 | 2022 | |
| Amgen INC. | $14.83 | 2024 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aisha Sethi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.